Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1017)	11/25/2003 12:06:34 AM
From: SemiBull	Respond to of 1139

S&P comments on ICOS Corp Monday November 24, 3:23 pm ET NEW YORK, Nov 24 - Standard & Poor's Ratings Services said today that the ratings on ICOS Corp. (NasdaqNM:ICOS - News; B-/Positive/--) would not be affected by the recent U.S. FDA marketing approval of the company's erectile dysfunction treatment, Cialis. While the approval is a significant positive development, Standard & Poor's expects ICOS to continue to experience losses for the next several years as it spends heavily to build marketing infrastructure to support the drug. Still, Cialis holds significant sales potential, given the growing market for erectile dysfunction treatments and the fact that it has a longer duration of action versus existing treatments, Pfizer Inc.'s Viagra and Bayer AG's Levitra. ICOS, along with its marketing partner Eli Lilly & Co. (AA/Stable/A-1+), are expected to launch the drug by year-end.